Brussels, Belgium, 28 March 2023: EHDEN (European Health Data & Evidence Network) is delighted to announce that Roche has become a partner of the EHDEN Consortium. They now join the 11 public partners, and 13 industry partners, adding their expertise, resources, and support in creating an ecosystem for working with real-world data across Europe. The private-public partnership is building a large-scale, federated network of data sources standardised to a common data model, which is enabling better health decisions, outcomes, and care for patients.
Roche will work with project partners on health data science, evidence generation and the development of plans for EHDEN’s future sustainability.
“We are delighted to welcome Roche to the consortium, it is an endorsement of EHDEN’s progress and achievements. We welcome the addition of Roche’s particular expertise and focus in real world evidence across pharma and diagnostics.
It will be important as we transition into longer term sustainability to have a broad foundation of partners, supporting our proposed path inclusive of research programmes, research services, training, and certification.”
Every day, patients are not receiving optimal healthcare because we are not able to tap into the unlimited potential of real-world data. In response to this, EHDEN was created as a public-private partnership under the framework of the Innovative Medicines Initiative 2-Joint Undertaking (IMI2-JU). EHDEN aspires to be the trusted observational research ecosystem to enable better health decisions, outcomes, and care, with a mission to provide a new paradigm for the discovery and analysis of health data in Europe, by building a large-scale, federated network of data sources standardised to a common data model.
To date, EHDEN’s Data Partner network includes 187 data sources from 29 countries with >850 million anonymous records that are being mapped to the Observational Medical Outcomes Partnership (OMOP) Common Data Model (CDM) OMOP common data model. These data partners are supported by 62 certified small-to-medium-sized enterprises, from 22 countries, who assist the data partners with their data mapping. The project is already generating real world evidence that has been published in almost 70 publications, and has helped improve treatment in multiple diseases, including in COVID-19.
The European Health Data & Evidence Network has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 806968. The JU receives support from the European Union’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).